ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BCL6 Molecular Glue LY4584180

Its studies are mostly in Lymphoma, Follicular, led by Eli Lilly.

Furthest: phase 1, since Nov 7, 20251 company-led study, 1 open or runningNext primary completion: Sep 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Nov 7, 2025Nov 7, 2025Sep 2028phase 1 · NCT07226843

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2025First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT07226843 · 460 planned · United States, France, Germany and more
  2. Oct 6, 2026Primary completion moved from 2027-04 to 2028-09Date moved laterphase 1 · +17 months · NCT07226843

Ahead

  1. Sep 2028Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT07226843

TargetBeta

BCL6 →read by rule
“An orally bioavailable molecular glue targeting B-cell lymphoma 6 protein (BCL6; BCL-6), ”NCIt, by rule

Other programs on BCL6

ProgramCompanyFurthest phaseStudies
BCL6 Degrader TLN-121ruletreeline-biosciences-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226843Lymphoma, Non-Hodgkin · United States, France, Germany and more1RecruitingSep 2028460

How it is read

Names in the registry

  • “LY4584180”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.